×
Home Current Archive Editorial board
News Contact
Review paper

Recanalization rate of proximal deep venous thrombosis related to therapeutic modality during six months follow-up

By
Alden Begić ,
Alden Begić

Department of Angiology, Clinic for Heart, Blood Vessel and Rheumatic Diseases, Clinical Centre University of Sarajevo, Sarajevo, Bosnia and Herzegovina

Edin Begić Orcid logo ,
Edin Begić
Contact Edin Begić

Department of Cardiology, General Hospital “Prim.dr Abdulah Nakaš“, Sarajevo, Bosnia and Herzegovina

Department of Pharmacology, School of Medicine, Sarajevo School of Science and Technology, Sarajevo, Bosnia and Herzegovina

Mirza Dilić ,
Mirza Dilić

Department of Science, School of Medicine, University of Sarajevo, Sarajevo, Bosnia and Herzegovina

Svjetlana Loga - Zec ,
Svjetlana Loga - Zec

Department of Pharmacology, School of Medicine, University of Sarajevo, Sarajevo, Bosnia and Herzegovina

Nermina Babić ,
Nermina Babić

Department of Physiology, School of Medicine, University of Sarajevo, Sarajevo, Bosnia and Herzegovina

Refet Gojak ,
Refet Gojak

Clinic for Infectious Diseases, Clinical Centre University of Sarajevo, Sarajevo, Bosnia and Herzegovina

Armin Šljivo
Armin Šljivo

Emergency Medicine Department of Canton Sarajevo, Sarajevo, Bosnia and Herzegovina

Abstract

Aim
To evaluate the efficacy (rate of recanalization) of therapy with novel oral anticoagulants (NOAC; rivaroxaban, apixaban)
compared to conventional treatment (low molecular weight heparin - LMWH and vitamin K antagonist) in the treatment of deep vein thrombosis (DVT) of the proximal segments of lower extremities.
Methods
The first group consisted of patients diagnosed with DVT and treated with NOAC (n = 100), while the second group consisted of patients diagnosed with DVT, who were treated by conventional treatment (low molecular weight heparin and vitamin K antagonists) (n = 100). In the first group, NOAC was included in the initial treatment. Patients in the second group were treated with LMWH for four days, and on the fifth day vitamin K antagonist was included in therapy, international ratio (INR) was titrated to therapeutic values (2.0-3.0), and then low molecular weight heparin was excluded from the therapy.
Results
There was a statistically significant difference in the estimated values of free lumen of the blood vessel between the examined groups after 30 days (p=0.0001), after 90 days (p=0.0001) and after 180 days (p=0.0001). After 180 days, the average free lumen values in the NOAC group were 85% (81-89%), which was significantly higher than the free lumen values in the second group, 73% (69-79%).
Conclusion
The use of NOAC represents more efficient treatment of DVT comparing to vitamin K antagonists.

References

1.
Nicholson M, Chan N, Bhagirath V, Ginsberg J. Prevention of venous thromboembolism in 2020 and beyond. J Clin Med. 2020. p. 2467.
2.
Oger E. Incidence of venous thromboembolism: a community-based study in Western France. Thromb Haemost. 2000. p. 657–60.
3.
Wendelboe A, Raskob G. Global burden of thrombosis: epidemiologic aspects. Circ Res. 2016. p. 1340–7.
4.
Stone J, Hangge P, Albadawi H, Wallace A, Shamoun F, Knuttien M, et al. Deep vein thrombosis: pathogenesis, diagnosis, and medical management. Cardiovasc Diagn Ther. 2017. p. 276–84.
5.
Stein P, Hull R, Saltzman H, Pineo G. Strategy for diagnosis of patients with suspected acute pulmonary embolism. Chest. 1993. p. 1553–9.
6.
Jezovnik M, Poredos P. Factors influencing the recanalisation rate of deep venous thrombosis. Int Angiol. 2012. p. 169–75.
7.
Swanson E. Doppler ultrasound imaging for detection of deep vein thrombosis in plastic surgery outpatients: a prospective controlled study. Aesthet Surg J. 2015. p. 204–14.
8.
Piati P, Peres A, De Andrade D, Jorge M, Toregeani J. Analysis of recanalization of deep venous thrombosis: a comparative study of patients treated with warfarin vs. rivaroxaban. J Vasc Bras. 2019.
9.
De Athayde Soares R, Matielo M, Neto B, Nogueira F, Almeida M, Sacilotto R, et al. Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Surgery. 2019. p. 1076–83.
10.
Lip G. The safety of NOACs in atrial fibrillation patient subgroups: a narrative review. Int J Clin Pract. 2019. p. 13285.
11.
Rahaghi F, Minhas J, Heresi G. Diagnosis of deep venous thrombosis and pulmonary embolism: new imaging tools and modalities. Clin Chest Med. 2018. p. 493–504.
12.
Budnik I, Brill A. Immune factors in deep vein thrombosis initiation. Trends Immunol. 2018. p. 610–23.
13.
Agnelli G, Buller H, Cohen A, Curto M, Gallus A, Johnson M, et al. AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013. p. 699–708.
14.
Cohen A, Bauersachs R. Rivaroxaban and the EIN-STEIN clinical trial programme. Blood Coagul Fibrinolysis. 2019. p. 85–95.
15.
Ageno W, Mantovani L, Haas S, Kreutz R, Monje D, Schneider J, et al. Turpie AG. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. Lancet Haematol. 2016. p. 12–21.
16.
Lin S, Wang Y, Zhang L, Guan W. Dabigatran must be used carefully: literature review and recommendations for management of adverse events. Drug Des Devel Ther. 2019. p. 1527–33.
17.
Minor C, Tellor K, Armbruster A. Edoxaban, a novel oral factor Xa inhibitor. Ann Pharmacother. 2015. p. 843–50.
18.
Beyer-Westendorf J, Verhamme P, Bauersachs R. Betrixaban for prevention of venous thromboembolism in acute medically ill patients. Eur Heart J. 2018. p. 16–22.

Citation

Authors retain copyright. This work is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

 

Article metrics

Google scholar: See link

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.